Compare ATLO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | TLSI |
|---|---|---|
| Founded | 1903 | 2010 |
| Country | United States | United States |
| Employees | 260 | 110 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.2M | 267.1M |
| IPO Year | 2001 | N/A |
| Metric | ATLO | TLSI |
|---|---|---|
| Price | $27.04 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 33.1K | ★ 218.2K |
| Earning Date | 04-16-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $41.93 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $69.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.09 | $3.42 |
| 52 Week High | $28.35 | $7.95 |
| Indicator | ATLO | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 30.16 |
| Support Level | $25.95 | $3.79 |
| Resistance Level | $28.28 | $5.51 |
| Average True Range (ATR) | 0.75 | 0.30 |
| MACD | -0.12 | -0.07 |
| Stochastic Oscillator | 61.49 | 8.42 |
Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.